Artificial Intelligence (AI) In Clinical Trials Market Report 2026

Artificial Intelligence (AI) In Clinical Trials Market Overview

• Artificial Intelligence (AI) In Clinical Trials market size has reached to $10.11 billion in 2025 • Expected to grow to $47.22 billion in 2030 at a compound annual growth rate (CAGR) of 35.3% • Growth Driver: Ai's Crucial Role In Reducing Clinical Trial Expenditure Fuels The Artificial Intelligence In The Clinical Trial Market Growth • Market Trend: Industry Players Embraces AI Feasibility And Recruitment Platforms To Redefine Artificial Intelligence In Clinical Trials Market • North America was the largest region and fastest growing region.

What Is Covered Under Artificial Intelligence (AI) In Clinical Trials Market?

Artificial intelligence in clinical trials refers to using artificial intelligence to design more efficient and adequate clinical trials. Artificial intelligence is used in clinical trials to improve trial design and optimisation through predictions about patient behaviour and drug efficacy. The main offerings of artificial intelligence (AI) in clinical trials are software and services. Software solutions refer to a type of custom-built or configured solution to solve a problem, and artificial intelligence software is used to enable faster and more accurate hypothesis generation and to understand the evolution of a disease. They are applied for various processes such as trial design, patient selection, site selection, and patient monitoring in oncology, neurological diseases and conditions, cardiovascular diseases, metabolic diseases, infectious diseases, immunology diseases, and others. It is used by pharmaceutical and biotechnology companies, contract research organizations, and others.

What Is The Artificial Intelligence (AI) In Clinical Trials Market Growth Forecast?

The artificial intelligence (AI) in clinical trials market size is expected to see exponential growth in the next few years. It will grow to $47.22 billion in 2030 at a compound annual growth rate (CAGR) of 35.3%. The growth in the forecast period can be attributed to expansion of decentralized clinical trials, increasing regulatory acceptance of AI tools, growth of precision medicine research, demand for cost efficient trials, advancements in healthcare analytics. Major trends in the forecast period include AI based trial design optimization, predictive patient enrollment modeling, data driven site selection, automated clinical outcome analysis, adaptive trial execution platforms.

Global Artificial Intelligence (AI) In Clinical Trials Market Segmentation

1) By Offering: Software, Services 2) By Process: Trial Design, Patient Selection, Site Selection, Patient Monitoring 3) By Application: Oncology, Neurological Disease And Condition, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology Disease, Other Applications 4) By End-User: Pharmaceutical And Biotechnology Company, Contract Research Organizations, Other End-Users Subsegments: 1) By Software: AI-driven Analytics Platforms, Data Management Tools, Patient Recruitment Solutions, Predictive Modeling Software 2) By Services: Consulting Services, Data Annotation And Labeling Services, Custom AI Model Development, Implementation And Integration Services

What Is The Driver Of The Artificial Intelligence (AI) In Clinical Trials Market?

The growing need to curb clinical trial costs is expected to propel the growth of artificial intelligence in the clinical trial market going forward. Clinical trials refer to research studies used to test medical, surgical, or behavioural interventions in people, and the costs of clinical trials include the cost of the research and the cost of patient care. Drug development and other clinical trial processes are costly by nature, and artificial intelligence is used to provide better drug discovery, better-designed and safer clinical trials, and improved patient outcomes at lower costs. For instance, in February 2023, according to Genetic Engineering and Biotechnology News, a US-based platform that provides the latest information on genetic engineering and biotechnology, developing a new drug among the top 20 global biopharma companies rose by 15% from $298 million in 2022 to approximately $2.3 billion in 2023, and this includes the costs incurred from developing a drug through clinical trials. Furthermore, in January 2023, according to a report published by the National Bureau of Economic Research (NBER), a US-based non-profit economic research organization, the adoption of AI within the next five years is expected to generate substantial cost savings in healthcare, ranging from 5 to 10% of healthcare spending, equating to approximately $200 billion to $360 billion in annual savings. Therefore, the growing need to curb clinical trial costs will drive artificial intelligence in the clinical trial market.

Key Players In The Global Artificial Intelligence (AI) In Clinical Trials Market

Major companies operating in the artificial intelligence (AI) in clinical trials market are Medable Inc.; PathAI inc.; Saama Technologies Inc.; TriNetX LLC; SymphonyAI Summit Inc.; Aktana; Nference Inc.; Insilico Medicine Inc.; Vineti Inc.; Innoplexus AG; Healx; AiCure Inc.; MEDIAN Technologies SA; Owkin Inc.; Science 37; Ardigen SA; Cyft Inc.; Unlearn.AI Inc.; Mendel AI; Deep Lens Inc.; Antidote Technologies Inc.; Arterys Inc.; Euretos BV; Halo Health Systems Inc.; Trials.AI Inc.; Transparency Life Sciences; BioAge Labs Inc.; Wave Life Sciences Ltd.; BioSymetrics Inc.

Global Artificial Intelligence (AI) In Clinical Trials Market Trends and Insights

Major companies operating in the artificial intelligence in clinical trials market are focusing on the development of innovative technologies, such as AI feasibility and recruitment platforms. AI feasibility and recruitment platforms are tools or systems that leverage artificial intelligence (AI) to assess the viability and potential success of clinical trials while also assisting in the efficient recruitment of suitable participants. For instance, in June 2023, a US-based research provider company, announced the launch of ‘ObjectiveScreen’. It is an AI-powered feasibility and recruitment platform that enhances clinical trial performance and results by improving patient identification, prequalification, and retention processes. ObjectiveScreen enables direct connectivity between clinical trial sites and the electronic health records (EHRs) of patients. The AI platform promotes patient engagement by simplifying and streamlining appointment scheduling and communication processes.

What Are Latest Mergers And Acquisitions In The Artificial Intelligence (AI) In Clinical Trials Market?

In January 2023, Paradigm Health Inc., a US-based healthcare technology company, acquired Deep Lens Inc. for an undisclosed amount. The acquisition aims to provide Paradigm with Deep Lens's platform, which enables equal access to trials for all patients while enhancing trial efficiency and reducing the barriers to participation for healthcare providers. Deep Lens Inc. is a US-based provider of an AI-driven cloud platform for clinical research.

Regional Insights

North America was the largest region in the artificial intelligence (AI) in clinical trials market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Artificial Intelligence (AI) In Clinical Trials Market?

The artificial intelligence (AI) in clinical trials market consists of revenues earned by entities by providing artificial intelligence in clinical trials services that include data security and compliance services, and consulting and implementation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The artificial intelligence (AI) in the clinical trials market also includes sales of clinical trial matching software, patient recruitment software and medical image analysis software. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Artificial Intelligence (AI) In Clinical Trials Market Report 2026?

The artificial intelligence (ai) in clinical trials market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence (ai) in clinical trials industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.